This is especially important given that up to 54.4% of patients undergoing surgery for lower extremity fractures may already have a Vitamin C deficiency [9]
The SMC announced on Monday that it had approved semaglutide (Wegovy) "when used together with diet, and exercise to reduce the risk of major cardiovascular events such as a stroke or heart attack, in adults who are overweight and have cardiovascular disease"
While results vary, most users start noticing changes within the first few weeks, with gradual, steady weight loss over time
Research involving this compound typically focuses on tissue repair, tendon, ligament, and gastrointestinal pathway research, with attention to receptor activity, cellular signaling, and measurable pathway response in experimental models